Disease-specific neuropathic symptoms
Study
Scope of investigation or explicitly identified community interest; not an established indication.3
Recovery
ARA 290
Cibinetide and small-fiber neuropathy
Investigational; this profile does not establish an approved use.
What does it do?
Amino-acid sequence
An exact sequence has not been verified for this formulation.
Length11 amino acids
Molecular weight · Da1,257.3 Da (peptide moiety)
Pharmacokinetics
Human data
Reported half-lifeAbout 20 minutes3
Route / formulationSubcutaneous, 4 mg
50%of reference level
Illustrative model using reported human data.
About 3% remaining after 1.67 h
Five half-lives in this simplified model. This is not a prediction of when effects stop.
About this estimate
The clinical paper reports a terminal half-life near 20 minutes for this formulation and route. Biological effect duration is a separate question.
Population: Healthy volunteers cited in the clinical paper
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Scope of evidence
Long-term safety and efficacy remain uncertain.3
Reported timelines
Reference & communityWeeks 1–2 / 2–4 / 4–6 / months 2–6
Reference sequence: pain/inflammation; nerve/tissue markers; peak response; persistent effects. Trial-specific findings cannot guarantee this progression.18
These are reported timelines, not a prediction of your response.
Doses & schedules
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubcutaneous | 4 mg | Once daily | Diabetic neuropathyAdults with type 2 diabetes and painful neuropathic symptomsHuman study | 28 days | 3 |
Population Adults with type 2 diabetes and painful neuropathic symptoms Context Placebo-controlled clinical research; not a general self-use schedule. | |||||
| SubQ | 4 mg daily | Once daily | Neuropathy TreatmentReference report | 28 days standard protocol | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQ | 1-8 mg daily | Once daily | Tissue ProtectionReference report | 28 days standard protocol | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| IV | 2 mg | 3x weekly | Acute InterventionReference report | 28 days standard protocol | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQ | 4 mg daily | Once daily for 28 days | Research ProtocolReference report | 28 days standard protocol | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 28 days standard protocol
- Break
- Variable based on indication, clinical trials used single 28-day cycles
Reported timing
Same time daily, preferably morning
Side effects & safety
Short exposure
The diabetes trial treated participants for 28 days, leaving long-term tolerability unresolved.
3Renal event
One participant stopped treatment after worsening renal insufficiency while furosemide was increased; causation was not established.
3Symptoms
Severe injection inflammation, allergy, new neurological symptoms, blood-count changes or worsening disease need assessment.
Evidence
Trial exclusions are not universal contraindications; long-term/pregnancy safety unestablished.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
9 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
NAD+
Caution reportedCellular/metabolic overlap.18
Reference report · Pep-Pedia label: Monitor CombinationGrowth hormone
Caution reportedGrowth-related overlap.18
Reference report · Pep-Pedia label: Use CautionBPC-157
Unverified pairingRepair rationale.18
Reference report · Pep-Pedia label: SynergisticTB-500
Unverified pairingRepair rationale.18
Reference report · Pep-Pedia label: SynergisticThymosin beta-4
Unverified pairingNo proven safe combination.18
Reference report · Pep-Pedia label: CompatibleEPO
Unverified pairingReference reports exclusion within 2 months.18
Reference report · Evidence context: Trial exclusionSemaglutide
Unverified pairingBackground medication use does not validate a combination.18
Reference report · Pep-Pedia label: CompatibleAnti-TNF biologics
Unverified pairingReference reports 6-month exclusion; not general timing advice.18
Reference report · Pep-Pedia label: Requires TimingOther peptides and medicines
Not establishedA controlled interaction assessment for this exact compound and formulation was not identified in the sources checked. Absence of interaction data is not evidence of compatibility.4
Research contextNo matching interactions. Try another name or filter.
Reconstitution calculator
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
Suggested final volume mL
Estimated water to add≈ mL
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
1 pen unit (one dial step)=
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Ingredients per unit
Other simple scales
Convert a specific amount
Enter an amount to calculate its volume and device setting.
Calculation & assumptions
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗Reconstitution
The study used a prepared buffered injection.3
Studied presentation
4 mg in 0.5 mL; phosphate buffer with sucrose and mannitol. This is not a bacteriostatic-water recipe.3
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
The source-specific step uses sterile water; its generic BAC-water banner is not treated as an additional formulation instruction.
- Solvents mentioned
- Sterile water
- Reported parameters
- Reported diluent volume: 1 mL. · Reported storage: immediate use or up to 24 hours at 2–8°C; protected from light.
The source describes gentle mixing and avoiding vigorous shaking.
Pep-Pedia permits slight cloudiness, but that appearance claim does not establish product quality or suitability.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearancePharmaceutical grade manufacturingReported appearanceProper peptide sequence verificationReported appearanceSterile lyophilized powderReported variationLight-sensitive formulationReported appearanceClinical batch documentationReported concernCloudy or discolored solution
18Vial sizes
1, 5 and 10 mg research solid
Cayman catalog examples for ARA 290 acetate. These do not establish vial sterility, clinical equivalence or a preparation method.5
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Storage notes
18Powder: -80°C long-term, 4°C medium-term; Reconstituted: use immediately or refrigerate up to 24 hours
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Pen & syringe measurements
Device units measure volume. Concentration determines the amount in mg.
1 notch = 0.01 mL
Documented 1-unit V2 models
- One dial increment
- 1 unit
- Cartridge capacity
- 3 mL
- Maximum setting
- 60 units · 0.60 mL
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
1 unit = 0.01 mL
100 units = 1 mL
- 10 units
- 0.10 mL
- 30-unit capacity
- 0.30 mL
- 50 / 100-unit capacity
- 0.50 / 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
Use the mL scale
mL syringes and calibrated pipettes
- 0.01 mL
- 10 µL
- 0.10 mL
- 100 µL
- Amount
- mL × mg/mL
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Device references
AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.Evidence limits
View findings →Long-term safety and efficacy remain uncertain.3
3 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
Human trialsCompound identity & other names
ARA 290, also called cibinetide, is an erythropoietin-derived peptide studied for tissue-protective signaling and neuropathic symptoms. Small human trials provide preliminary evidence; they do not establish general nerve-repair treatment.
Other names: Cibinetide · Helix B surface peptide
Investigational; this profile does not establish an approved use.
How it may work
Proposed innate-repair receptor signaling aims to protect tissue without stimulating red-cell production.18
Diabetic neuropathy trial
In a 49-person diabetes trial, symptom scores improved, but sensory thresholds did not. The corneal nerve signal was concentrated in a subgroup with reduced baseline nerve density.
3Research areas and evidence gaps
Disease-specific neuropathic symptoms. Scope of investigation or explicitly identified community interest; not an established indication.3
- Long-term safety and efficacy remain uncertain.
- The evidence does not validate the identity, purity or handling of a separately sourced research product.
Additional uses listed by Pep-Pedia
Nerves. Peripheral/corneal nerve repair, diabetic neuropathy and neuropathic pain; CNS stroke/TBI claims are preclinical.18
Inflammation / immune. Cytokines, colitis, islet transplantation and rheumatoid-arthritis research.18
Tissue / aging. Diabetic wounds, angiogenesis, cardiac injury and aging-heart models.18
Community reports Unvalidated
Pep-Pedia reports use in the research-peptide community. These reports are not clinical evidence.4
Community protocol tables are unvalidated descriptions, not treatment instructions.
Search coverage and review status
Additional primary or regulatory sources were checked. No further 2025–2026 exact-compound clinical outcome study was identified in this targeted search; this is not evidence that none exists.
- Checked
- 2026-10-12
- Search
- ARA 290 cibinetide 2025 2026 randomized trial study PubMed; ARA 290 half-life human study
- Catalog
- Pep-Pedia ↗ · 14 listed references retained
- Targeted search, not a systematic or exhaustive review.
- Retained bibliography entries marked Bibliography only have not been independently verified.
- Distinct URLs may refer to the same publication; component and formulation boundaries remain important.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 16 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 18 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 12 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Would recommend
The source hides 6 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 3 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “1104 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1ARA 290 improves metabolic control and neuropathic symptoms in patients with type 2 diabetesPrimary source checked
AI-PREPARED SUMMARY
A small placebo-controlled diabetes trial found improved PainDetect scores and modest glycemic changes after 28 days.
Pep-Pedia bibliography · Checked 2026-10-12
2ARA 290 improves metabolic control and neuropathic symptoms in patients with type 2 diabetesPrimary source checked
AI-PREPARED SUMMARY
A small placebo-controlled diabetes trial found improved PainDetect scores and modest glycemic changes after 28 days.
Pep-Pedia bibliography · Checked 2026-10-12
3ARA 290 improves metabolic control and neuropathic symptoms in patients with type 2 diabetesPrimary source checked
AI-PREPARED SUMMARY
A small placebo-controlled diabetes trial found improved PainDetect scores and modest glycemic changes after 28 days.
Diabetic neuropathy trial
In a 49-person diabetes trial, symptom scores improved, but sensory thresholds did not. The corneal nerve signal was concentrated in a subgroup with reduced baseline nerve density.
Additional research · Checked 2026-10-12
4Pep-Pedia: Ara 290Community source checked
AI-PREPARED SUMMARY
Secondary community overview checked on 12 October 2026. Its practice tables and efficacy claims are not independently validated clinical guidance.
5Cayman Chemical: ARA 290 acetate, item 34943Catalog checked
AI-PREPARED SUMMARY
Supplier identity and packaging record for research solid: 1, 5 and 10 mg. These are catalog examples, not a survey of common vial sizes or a product endorsement. The supplier specifies no human or veterinary use.
Additional research · Checked 2026-10-12
6Yao, X., Panichpisal, K., Kurtzman, N., et al. (2021). ARA 290 protects human isolated pancreatic islets against lipotoxicity via reducing ER stress. Cell Transplantation, 30, 09636897211039739.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Cultured human islets had better viability and function under inflammatory stress. This was a cell experiment, not diabetes treatment in patients.
Reported population / model
Human islets
Reported study details
100 nM · 48 hours · Improved viability and function
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Lois, N., McCarter, R.V., O'Neill, C., et al. (2020). Cibinetide for the treatment of diabetic macular edema: A randomized controlled pilot study. Journal of Clinical Medicine, 9(7), 2225.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Nine patients reported better quality of life, while vision responses varied. The uncontrolled design limits causal conclusions.
Reported population / model
Human
Reported study details
4 mg SC daily · 12 weeks · Improved quality of life, variable visual outcomes
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Sarcoidosis Neuropathy Phase 2b Trial (2017)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The 64-person trial reportedly found a 23% increase in corneal nerve-fiber area at 4 mg and pain changes in more severe cases.
Reported population / model
Human
Reported study details
1-8 mg SC daily · 28 days · 23% increase in corneal nerve fiber area at 4 mg dose
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Brines, M., Swartjes, M., van Velzen, M., et al. (2013). ARA 290 in the treatment of pain and inflammation in subjects with rheumatoid arthritis. Annals of the Rheumatic Diseases, 72(Suppl 3), A672-A673.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: In 15 uncontrolled patients, pain scores fell 27–29 mm; one good and one moderate EULAR response were reported.
Reported population / model
Human
Reported study details
2mg IV · 1-3x/week for 4 weeks · 15 patients with active RA
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Myocardial Infarction Protection Study (2012)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Mouse heart-injury experiments reported smaller infarcts and better survival after one IV dose.
Reported population / model
Mouse
Reported study details
24 μg/kg IV · Single dose · Reduced infarct size and improved survival
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11Stroke Neuroprotection Research (2011)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rat stroke experiments reported reduced damaged-brain volume and better functional measures, with proposed tissue-protection receptor signaling.
Reported population / model
Rat
Reported study details
300 μg/kg IV · Single dose · Reduced stroke volume and improved outcomes
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12Brines, M., Patel, N.S., Villa, P., et al. (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences, 105(31), 10925-10930.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
13Dahan, S., Andersen, A.S., Moeller, H.J., et al. (2013). ARA 290, a nonerythropoietic EPO analog, for treatment of patients with sarcoidosis and chronic neuropathic pain. Molecular Medicine, 19(1), 334-345.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
14Culver, D.A., Dahan, S., Sharma, S., et al. (2017). Clinical efficacy of ARA 290 (cibinetide) in sarcoidosis-associated neuropathy. Investigative Ophthalmology & Visual Science, 58(6), BIO52-BIO60.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
15Al-Onaizi, M., Parfitt, G.M., Kolisnyk, B., et al. (2022). The erythropoietin-derived peptide ARA 290 reverses the effects of chronic stress on depressive-like behavior and neuroplasticity markers. Frontiers in Pharmacology, 13, 896601.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
16Collino, M., Thiemermann, C., Cerami, A., et al. (2015). Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacology & Therapeutics, 151, 32-40.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
17Dahan, S., Andersen, A.S., Moeller, H.J., et al. (2013). ARA 290, a nonerythropoietic EPO analog, for treatment of patients with sarcoidosis and chronic neuropathic pain. Molecular Medicine, 19(1), 334-345.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
18Pep-Pedia: ARA 290 — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12